Venous thrombembolism, thrombophilic defects, combined oral contraception and anticoagulation

被引：5

作者：

Ott, Johannes ^{[1
,2
]}

Promberger, Regina ^{[3
]}

Kaufmann, Ulrike ^{[2
]}

Huber, Johannes C. ^{[2
]}

Frigo, Peter ^{[2
]}

机构：

[1] Med Univ Vienna, Dept Obstet & Gynaecol, A-1090 Vienna, Austria

[2] Med Univ Vienna, Dept Gynaecol Endocrinol & Reprod Med, A-1090 Vienna, Austria

[3] Med Univ Vienna, Dept Surg, A-1090 Vienna, Austria

来源：

ARCHIVES OF GYNECOLOGY AND OBSTETRICS | 2009年 / 280卷 / 05期

关键词：

Thrombembolism; Anticoagulation; Contraception; Protein S deficiency; Oral contraceptives; PROTEIN-S DEFICIENCY; INHERITED THROMBOPHILIA; CLINICAL-MANIFESTATIONS; BLEEDING COMPLICATIONS; CEREBRAL VEIN; RISK; THROMBOSIS; THROMBOEMBOLISM; CARRIERS; ANTITHROMBIN;

D O I：

10.1007/s00404-009-0997-0

中图分类号：

R71 [妇产科学];

学科分类号：

100211 ;

摘要：

Several genetic polymorphisms increase the risk for venous thrombembolism (VTE). In particular, combined oral contraceptives (COCs) are known to enhance the risk for VTE and are therefore contraindicated. We present here the case of a patient with protein S deficiency, who has used COCs together with anticoagulatory therapy (Phenprocoumon) after suffering from deep venous thromboses for 4 years. At the time of her first consultation at our clinic, the ultrasound examination showed a complete involution of her venous thrombosis. COCs can be used in patients with thrombogenic mutations and anticoagulatory therapy in individual cases.

引用

页码：811 / 814

页数：4

共 23 条

[11] Does use of hormonal contraceptives among women with thrombogenic mutations increase their risk of venous thromboembolism? A systematic review [J].